Skip to main content

Market Overview

Recap: Biogen Q1 Earnings



Shares of Biogen (NASDAQ:BIIB) moved higher by 1.4% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share were down 41.58% year over year to $5.34, which beat the estimate of $5.04.

Revenue of $2,694,000,000 declined by 23.77% from the same period last year, which beat the estimate of $2,650,000,000.


The upcoming fiscal year's EPS expected to be between $17.50 and $19.00.

The upcoming fiscal year's revenue expected to be between $10,450,000,000 and $10,750,000,000.

How To Listen To The Conference Call

Date: Apr 22, 2021

Time: 08:00 AM

ET Webcast URL:


52-week high: $363.92

52-week low: $223.25

Price action over last quarter: Up 2.29%

Company Description

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.


Related Articles (BIIB)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at